Göldlin, Martina; Radojewski, Piotr; Siepen, Bernhard; Müller, Madlaine; Wiest, Roland; Mordasini, Pasquale; Polymeris, Alexandros; Engelter, Stefan T; Lyrer, Philippe; Z'Graggen, Werner; Fischer, Urs; Seiffge, David (2021). [Intracerebral haemorrhage - acute event and chronic disease]. Therapeutische Umschau, 78(6), pp. 320-327. Hogrefe 10.1024/0040-5930/a001276
Full text not available from this repository.Intracerebral haemorrhage - acute event and chronic disease Abstract. Intracerebral hemorrhage accounts for 10-15% of all strokes and approximately 1'500-2'000 patients per year in Switzerland. Acute treatment by multi-disciplinary experts at certified stroke units and stroke centers is important to provide optimal care. A simple ABC-care bundle (revert anticoagulation, control blood pressure, inform neurosurgeon) decreases poor outcome. Despite a high mortality, one third of patients are functionally independent after intracerebral hemorrhage contradicting widespread pessimism. About 80% of all intracerebral hemorrhage are attributable to different types of cerebral small vessel disease. Relative and absolute risks of recurrent hemorrhage and ischemic stroke differ significantly. Patients with intracerebral hemorrhage are vascular high-risk patients with chronic cerebrovascular disease. Long-term outpatient management should include neurovascular specialists to deal with important decisions (blood pressure management, antithrombotic therapy including anticoagulation, specialized neurorehabilitation to improve neurocognitive deficits, therapy of possible complications such as epilepsy) to provide optimal and individual care to patients. Currently ongoing randomized controlled trials will provide important results in the next years further improving treatment of intracerebral hemorrhage.